Non Invasive Diagnostics Market for Fibrotic Diseases

Non Invasive Diagnostics Market for Fibrotic Diseases

The non invasive diagnostics market for fibrotic diseases is estimated to be worth $1.6 billion in 2020 and is expected to grow at CAGR of 10% during the forecast period. With changing lifestyle and subsequently rising numbers of chronic ailments (such as obesity and diabetes), the prevalence of fibrotic diseases has also witnessed a surge globally. For instance, liver fibrosis is a common secondary pathological development observed in patients suffering from metabolic / cholestatic diseases, individuals consuming excessive quantities of alcohol and patients suffering from viral hepatitis. With non-alcoholic fatty liver disease (NAFLD) (subsequently progressing to nonalcoholic steatohepatitis / NASH drugs) being the primary cause of liver disease, nearly 4.5 million adults in the US have been diagnosed with this condition in 2018. Similarly, idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, life-threatening interstitial lung disease reported in individuals with high exposure to deadly pollutants, radiation treatments and chemotherapeutic drugs. Although, IPF is a rare disease, nearly 40,000 new cases are diagnosed in the Europe, annually. Early diagnosis of fibrotic diseases is crucial to the condition being successfully managed / treated. However, timely diagnosis of this medical condition has been a known challenge due to the absence of overt symptoms. When symptoms appear, the patient suspected with the disease is suggested to undergo tissue biopsy for the disease confirmation. Considering that a tissue biopsy, a painful and traumatic procedure, is the currently accepted standard of diagnosis, there is a stigma associated with the process. Moreover, owing to the invasive nature of the test, it cannot be frequently repeated in order to monitor disease progress or validate therapeutic outcomes. There is, therefore, an established unmet need for a safer and more patient friendly diagnostic method.

Advances in the field of biotechnology have enabled the development of several minimally invasive / non-invasive approaches for diagnosis of fibrotic diseases which include imaging diagnostics and biomarker-based assays. Among the biomarker-based tests, liquid biopsy (based on the analysis of biofluids such as blood, urine and / or plasma), a relatively new concept, has emerged as a versatile and promising non-invasive cancer diagnostic method for the detection of not only cancer but also fibrosis. In addition, there are numerous forms of genetic analysis which enable accurate diagnosis of diseases such as cystic fibrosis; these biomarker and genetic tests are backed by clinical data, validating their relevance and applicability across several types of fibrotic indications, and are anticipated to replace the existing invasive diagnostic techniques in the future.

Key Companies in Non Invasive Diagnostics Market for Fibrotic Diseases

Examples of key companies engaged in non invasive diagnostics market for fibrotic diseases (which have also been profiled in this market report; the complete list of companies is available in the full report) include BioPredictive, Echosens, ELITechGroup, Fibronostics, Fujirebio, GenPath Diagnostics, HepQuant, LabCorp, Luminex, Oasis Diagnostics, PerkinElmer and Yourgene Health. This market report includes an easily searchable excel database of all the companies providing non invasive diagnostics for fibrotic disease diagnosis, worldwide.

Scope of the Report

The “Non Invasive Diagnostics Market for Fibrotic Diseases, 2020-2030” market report features an extensive study of the current market landscape, market size, market share, market growth, market forecast, market outlook and future opportunities of the non invasive diagnostics market for fibrotic diseases. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in non invasive diagnostics market for fibrotic diseases during the forecast period.

In addition to other elements, the market research report includes:

• A detailed assessment of the current market landscape of non-invasive diagnostics for fibrosis, providing information and analyses based on a number of relevant parameters, such as status of development (available or under development) of products, type of product (assay-kits, devices and software), application area (diagnostics, monitoring, screening and research), target fibrotic disease (cardiac fibrosis, cystic fibrosis, liver fibrosis, pulmonary fibrosis and renal fibrosis), type of sample (blood, saliva, mucus and buccal swab), type of biomarker, end user (hospitals / clinics, research institutes and self-tests), turnaround time and requirement of medical assistance. In addition, the chapter includes information on the device developers, including details on year of establishment, company size and location of headquarters.
• Elaborate profiles of key players developing non-invasive diagnostics for fibrosis, featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and an informed future outlook.
• An analysis of the partnerships that have been inked by stakeholders in non invasive diagnostics market for fibrotic diseases since 2016, distribution agreements, acquisitions, product development agreements, joint venture, licensing (specific to affiliated products), product utilization agreements, clinical trial agreements  product development and commercialization and others relevant types of deals. 
• A detailed analysis of completed, ongoing and planned clinical studies for non-invasive diagnostics of fibrotic diseases, based on various relevant parameters, such as current trial status, trial registration year, phase of development, study design, study focus, product types, target fibrotic disease and enrolled patient population, highlighting leading sponsors, popular products and regional distribution of trials.
• An insightful analysis of potential biomarkers for non-invasive diagnosis of liver fibrosis, taking into consideration biomarker type (physical / biological) and measurement indexes, highlighting leading sponsors involved in the clinical evaluation of biomarkers.
• An in-depth analysis of over 13,000 patents that have been filed / granted for non-invasive diagnostics for fibrotic diseases, till May 2020, highlighting key trends associated with these patents, across type of patent, publication year and application year, regional applicability, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent benchmarking and valuation.  

The key objective of non invasive diagnostics market for fibrotic diseases report is to provide a detailed market analysis in order to estimate the existing market size, market trends, market value, statistics and future opportunity for non invasive diagnostics market for fibrotic diseases during the forecast period. Based on multiple parameters, such as disease prevalence, anticipated adoption of non-invasive approaches for fibrotic diseases and their likely selling price, we have provided informed estimates on the evolution of the market for the forecast period 2020-2030. The market report also features the likely distribution of the current and forecasted opportunity across [A] target fibrotic disease (cystic fibrosis, liver fibrosis and pulmonary fibrosis) [B] end user (hospitals / clinics and research institutes) and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America and Middle East and North Africa). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in the market report were also influenced by discussions held with multiple stakeholders in non invasive diagnostics market for fibrotic diseases. The market research report features detailed transcripts of interviews held with the following individuals:

• Garry de Jong (Chief Executive Officer, Repeat Diagnostics)
• Herman Steen (Chief Executive Officer, Biorion)
• Lawrence Cohen (Chief Executive Officer) and Charles Swindell (Chief Scientific Officer), Glycotest

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this market research report are in USD, unless otherwise specified.